PGGM Investments Acquires 8,382 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

PGGM Investments lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,067 shares of the biopharmaceutical company’s stock after purchasing an additional 8,382 shares during the period. PGGM Investments’ holdings in Gilead Sciences were worth $7,053,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $26,000. Tompkins Financial Corp boosted its position in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $40,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.2 %

Shares of Gilead Sciences stock traded up $0.15 on Friday, hitting $65.42. The company had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. The stock has a market capitalization of $81.45 billion, a price-to-earnings ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. Gilead Sciences, Inc. has a 1 year low of $64.63 and a 1 year high of $87.86. The stock has a 50 day moving average of $71.28 and a 200-day moving average of $76.25. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $1.37 earnings per share. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.82 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Mizuho dropped their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. UBS Group dropped their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $83.87.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.